CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of small cell lung cancer (SCLC).
  
  OVERVIEW OF ACTIVITY
  Small cell lung cancer (SCLC) accounts for approximately 10% to 15% of lung cancer diagnoses per year. Nearly all cases of SCLC are attributable to cigarette smoking and appear to be most common in heavy smokers. SCLC is characterized by early development of widespread metastases, and although it is initially highly sensitive to chemotherapy and radiation therapy, many patients eventually die of recurrent disease. The standard treatment for SCLC has largely not changed over the past 30 years, creating a critical need to evaluate novel strategies for the management of this disease. However, a number of important data sets with the use of immune checkpoint inhibitors have recently yielded promising successes, such that the clinical management of SCLC, for the first time in many years, has witnessed substantial disruption. Although several consensus- and evidence-based treatment guidelines are currently available and aim to assist clinicians with making clinical decisions in the face of this dynamic environment, many areas of controversy persist within academic and community settings. These video proceedings from a CME symposium held during the IASLC 2019 North America Conference on Lung Cancer feature presentations and perspectives from leading lung cancer investigators regarding the integration of immune checkpoint inhibitors into the management of SCLC. By providing information on important developments, this activity will assist medical oncologists and other healthcare professionals to address existing management uncertainties and determine the current and future role of immune checkpoint inhibitors in this disease.
  
  LEARNING OBJECTIVES

  • Formulate up-to-date management strategies for SCLC, considering the roles of local therapy, chemotherapy and immunotherapy.
  • Appraise available and emerging research data and current guideline recommendations informing the use of immune checkpoint inhibitors for patients with SCLC, and discern how these agents can be optimally employed in clinical practice.
  • Review the recent FDA approval of atezolizumab in combination with carboplatin and etoposide as first-line therapy for patients with extensive-stage SCLC, and consider how this strategy can be appropriately and safely integrated into clinical practice.
  • Appreciate emerging Phase III data investigating the role of durvalumab in combination with platinum-based chemotherapy for newly diagnosed extensive-stage SCLC, and apply this information to identify patients who may be appropriate for future treatment with this novel approach.
  • Recall the design of ongoing clinical trials evaluating other anti-PD-1/PD-L1-based strategies in SCLC, and counsel appropriate patients about availability and participation.
  • Recognize immune-related adverse events and other common side effects associated with anti-PD-1/PD-L1 antibodies alone or in combination with other systemic agents, and formulate supportive management strategies to minimize and/or manage these toxicities.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:
  
  Moderator
  
  David R Spigel, MD
  Chief Scientific Officer
  Program Director, Lung Cancer Research
  Sarah Cannon Research Institute
  Nashville, Tennessee
  
  Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Evelo Biosciences, Foundation Medicine, Genentech, GlaxoSmithKline, Illumina, Lilly, Merck, Moderna, Nektar, Novartis, Pfizer Inc, PharmaMar, Precision Medicine Group, Roche Laboratories Inc, Takeda Oncology, TRM Oncology; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Aeglea BioTherapeutics, Amgen Inc, ARMO Biosciences, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Celldex Therapeutics, Clovis Oncology, Daiichi Sankyo Inc, EMD Serono Inc, Foundation Medicine, G1 Therapeutics, Genentech, GlaxoSmithKline, GRAIL, Ipsen Biopharmaceuticals Inc, Lilly, Merck, Nektar, Neon Therapeutics, Novartis, OncoGenex Pharmaceuticals Inc, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology, Tesaro, A GSK Company, Transgene, University of Texas Southwestern Medical Center Simmons Comprehensive Cancer Center; Paid Travel: AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, EMD Serono Inc, Genentech, Genzyme Corporation, Intuitive Surgical, Lilly, Merck, Pfizer Inc, Purdue Pharma, Spectrum Pharmaceuticals Inc, Sysmex Corporation.
  
  FACULTY
  
  Anna Farago, MD, PhD
  Thoracic Medical Oncologist
  Massachusetts General Hospital Cancer Center
  Assistant Professor of Medicine
  Harvard Medical School
  Boston, Massachusetts
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, PharmaMar, Roche Laboratories Inc; Contracted Research: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, PharmaMar, Roche Laboratories Inc.
  
  Ramaswamy Govindan, MD
  Professor of Medicine
  Director, Section of Oncology
  Anheuser-Busch Endowed Chair in Medical Oncology
  Washington University School of Medicine
  St Louis, Missouri
  
  Advisory Committee: AbbVie Inc, Achilles Therapeutics; Consulting Agreement: Amgen Inc.
  
  RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, Genmab, Genomic Health Inc, Gilead Sciences Inc, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite Pharma Inc, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantor.
  
  This activity is supported by an educational grant from AstraZeneca Pharmaceuticals LP.
  
  Hardware/Software Requirements:
  A high-speed Internet connection
  A monitor set to 1280 x 1024 pixels or more
  Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
  Adobe Flash Player 27 plug-in or later
  Adobe Acrobat Reader
  (Optional) Sound card and speakers for audio
  
  Release date: December 2019
  Expiration date: December 2020